CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing Post author: Post published:December 4, 2023 Post category:uncategorized CN Bio today announced its PhysioMimix® assay for Non-alcoholic steatohepatitis (NASH). You Might Also Like Immunotherapy significantly improves survival rates for advanced lung cancer patients, study finds August 5, 2024 Dairy products linked to lower colorectal cancer risk, thanks to calcium January 10, 2025 New study warns of potential pandemic risk from α-H1N2 swine flu virus June 23, 2024
Immunotherapy significantly improves survival rates for advanced lung cancer patients, study finds August 5, 2024